Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2019
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2019
SUMMARY
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2019, outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer. The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Metabolic Disorders, Ophthalmology and Respiratory which include indications Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Allergic Conjunctivitis, Alzheimer's Disease, Asthma, Breast Cancer, Carcinoid Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Crohn's Disease (Regional Enteritis), Depression, Duodenal Cancer, Idiopathic Pulmonary Fibrosis, Insulin Resistance, Ischemic Stroke, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Myocardial Ischemia, Non-Small Cell Lung Cancer, Obesity, Pancreatic Cancer, Pheochromocytoma, Post-Traumatic Stress Disorder (PTSD), Recurrent Glioblastoma Multiforme (GBM), Sarcomas, Septic Shock, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Solid Tumor, Testicular Cancer, Thymoma (Thymic Epithelial Tumor), Triple-Negative Breast Cancer (TNBC), Type 2 Diabetes, Ulcerative Colitis and Uveitis.
Furthermore, this report also reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2019, outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer. The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Metabolic Disorders, Ophthalmology and Respiratory which include indications Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Allergic Conjunctivitis, Alzheimer's Disease, Asthma, Breast Cancer, Carcinoid Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Crohn's Disease (Regional Enteritis), Depression, Duodenal Cancer, Idiopathic Pulmonary Fibrosis, Insulin Resistance, Ischemic Stroke, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Myocardial Ischemia, Non-Small Cell Lung Cancer, Obesity, Pancreatic Cancer, Pheochromocytoma, Post-Traumatic Stress Disorder (PTSD), Recurrent Glioblastoma Multiforme (GBM), Sarcomas, Septic Shock, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Solid Tumor, Testicular Cancer, Thymoma (Thymic Epithelial Tumor), Triple-Negative Breast Cancer (TNBC), Type 2 Diabetes, Ulcerative Colitis and Uveitis.
Furthermore, this report also reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)
- The report reviews Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics and enlists all their major and minor projects
- The report assesses Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Protein Phosphatase 2A (PP2A or EC 3.1.3.16) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Overview
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Companies Involved in Therapeutics Development
Lixte Biotechnology Holdings Inc
PEP-Therapy SAS
Re-Pharm Ltd
SupremeCure Pharma Inc
Velacor Therapeutics Pty Ltd
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Drug Profiles
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEP-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-0217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate PP2A for Castration Resistant Prostate Cancer and Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PPP2R2A for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VEL-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Dormant Products
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Product Development Milestones
Featured News & Press Releases
Dec 04, 2019: First two patients enrolled in National Cancer Institute trial of the ability of Lixte Biotechnology’s LB-100 to enter recurrent malignant Brain Tumors
Aug 06, 2019: The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings’ LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas
Jul 18, 2019: First patient enrolled in phase 1b/2 trial of Lixte Biotechnology’s LB-100 in low or intermediate-1 Risk Myelodysplastic Syndrome
Jun 25, 2019: Lixte Biotechnology's PP2A inhibitor, LB-100, improves brain function and motor impairment in a mouse model of Angelman syndrome, a rare human neurodevelopmental disorder
May 16, 2019: PEP-Therapy reports positive results from GLP-Toxicity study of PEP-010 drug candidate
May 15, 2019: Lixte Biotechnology's LB-100 to be evaluated by the National Cancer Institute in a clinical study of LB-100's ability to enter recurrent Glioblastoma Multiforme brain tumors
Nov 05, 2018: FDA approves Lixte Biotechnology’s IND to conduct a phase 1b/2 trial of LB-100 in patients with myelodysplastic syndrome at Moffitt Cancer Center
Oct 09, 2018: Lixte Biotechnology files an IND with the FDA to conduct a phase 1b/2 trial of LB-100 in patients with myelodysplastic syndrome at Moffitt Cancer Center
Apr 17, 2018: PEP-Therapy, Institut Curie and Gustave Roussy Obtain 2,9 M€ to Develop a Novel Peptide in Oncology
Feb 09, 2018: LB-100, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitor, Sensitizes BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase Inhibitors
Jun 13, 2017: Re-Pharm and Cresset Discovery Services to attend BIO International for partnering
Apr 17, 2017: Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model
Mar 09, 2017: Late-Breaking Abstract on LB-100, Lixte Biotechnologys Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting
Jan 04, 2017: First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research
Nov 03, 2016: Re-Pharm to present at IDDST, Nanjing, China and available for one-to-one meetings
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Overview
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Companies Involved in Therapeutics Development
Lixte Biotechnology Holdings Inc
PEP-Therapy SAS
Re-Pharm Ltd
SupremeCure Pharma Inc
Velacor Therapeutics Pty Ltd
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Drug Profiles
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEP-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-0217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate PP2A for Castration Resistant Prostate Cancer and Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PPP2R2A for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VEL-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Dormant Products
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Product Development Milestones
Featured News & Press Releases
Dec 04, 2019: First two patients enrolled in National Cancer Institute trial of the ability of Lixte Biotechnology’s LB-100 to enter recurrent malignant Brain Tumors
Aug 06, 2019: The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings’ LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas
Jul 18, 2019: First patient enrolled in phase 1b/2 trial of Lixte Biotechnology’s LB-100 in low or intermediate-1 Risk Myelodysplastic Syndrome
Jun 25, 2019: Lixte Biotechnology's PP2A inhibitor, LB-100, improves brain function and motor impairment in a mouse model of Angelman syndrome, a rare human neurodevelopmental disorder
May 16, 2019: PEP-Therapy reports positive results from GLP-Toxicity study of PEP-010 drug candidate
May 15, 2019: Lixte Biotechnology's LB-100 to be evaluated by the National Cancer Institute in a clinical study of LB-100's ability to enter recurrent Glioblastoma Multiforme brain tumors
Nov 05, 2018: FDA approves Lixte Biotechnology’s IND to conduct a phase 1b/2 trial of LB-100 in patients with myelodysplastic syndrome at Moffitt Cancer Center
Oct 09, 2018: Lixte Biotechnology files an IND with the FDA to conduct a phase 1b/2 trial of LB-100 in patients with myelodysplastic syndrome at Moffitt Cancer Center
Apr 17, 2018: PEP-Therapy, Institut Curie and Gustave Roussy Obtain 2,9 M€ to Develop a Novel Peptide in Oncology
Feb 09, 2018: LB-100, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitor, Sensitizes BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase Inhibitors
Jun 13, 2017: Re-Pharm and Cresset Discovery Services to attend BIO International for partnering
Apr 17, 2017: Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model
Mar 09, 2017: Late-Breaking Abstract on LB-100, Lixte Biotechnologys Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting
Jan 04, 2017: First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research
Nov 03, 2016: Re-Pharm to present at IDDST, Nanjing, China and available for one-to-one meetings
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Lixte Biotechnology Holdings Inc, H2 2019
Pipeline by PEP-Therapy SAS, H2 2019
Pipeline by Re-Pharm Ltd, H2 2019
Pipeline by SupremeCure Pharma Inc, H2 2019
Pipeline by Velacor Therapeutics Pty Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Lixte Biotechnology Holdings Inc, H2 2019
Pipeline by PEP-Therapy SAS, H2 2019
Pipeline by Re-Pharm Ltd, H2 2019
Pipeline by SupremeCure Pharma Inc, H2 2019
Pipeline by Velacor Therapeutics Pty Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Lixte Biotechnology Holdings Inc
PEP-Therapy SAS
Re-Pharm Ltd
SupremeCure Pharma Inc
Velacor Therapeutics Pty Ltd
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Lixte Biotechnology Holdings Inc
PEP-Therapy SAS
Re-Pharm Ltd
SupremeCure Pharma Inc
Velacor Therapeutics Pty Ltd
